Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux vs enoxaparin vs rivaroxaban for prevention of venous thromboembolism after hip fracture surgery
ChiCTR2100042259Phase 4Recruiting
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
- Start
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of fondaparinux, enoxaparin and rivaroxaban in venous thromboembolism (VTE) (3 arms), sponsored by Affiliated Hospital of North Sichuan Medical College. Primary endpoint: Incidence of deep vein thrombosis. Started Jan 2021; status: recruiting.
02
Drugs
fondaparinuxenoxaparinrivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ChiCTR2100042259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042259.